find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
33
Clinical Trials
Multiple Myeloma
Phase I/II
Accepting Patients
nct/study# NCT03732703 / MMRC-085
Myeloma-Developing Regimens Using Genomics (Mydrug) (Genomics Guided Multi-Arm Trial Of Targeted Agents Alone Or In Combination With A Backbone Regimen)
Learn More
Multiple Myeloma
Phase I/II
Accepting Patients
nct/study# NCT04150965 / MMRC-089
A Phase I/II Assessment Of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) And Anti-TGIT (BMS-986207)
Learn More
Multiple Myeloma
Phase I/II
Accepting Patients
nct/study# NCT03215030 / TAK-573-1501
A Phase 1/2 Open-Label Study To Investigate The Safety And Tolerability, Efficacy, Pharmacokinetics, And Immunogenicity Of TAK-573 As A Single Agent In Patients With Refractory Multiple Myeloma
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT02675452 / 20150161
A Phase I In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AMG 176 In Subjects With Relapsed Or Refractory Multiple Myeloma
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04093596 / ALLO-715-101
A Single-Arm, Open-Label, Phase 1 Study Of The Safety, Efficacy, And Cellular Kinetics/Pharmacodynamics Of ALLO-715 To Evaluate An Anti-BCMA Allogeneic CAR T Cell Therapy In Subjects With Relapsed/Refractory Multiple Myeloma
Learn More
Multiple Myeloma
Phase II
Accepting Patients
nct/study# NCT03601078 / BB2121-MM-002
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of BB2121 In Subjects With Multiple Myeloma (Karmma-2)
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.